Capabilities
One plant. Four capability lines. A catalog built to hold both.
Naprod manufactures oncology, anesthesia, and critical-care injectables, plus the tablets, capsules, and active ingredients that sit alongside them, from a single site in Tarapur, Maharashtra.
200+ products in the catalog, spanning finished-dose formulations and active pharmaceutical ingredients, produced under EU-GMP and WHO-GMP process controls.
Installed capacity
Seven production lines, one site
Annual installed capacity at 300 production days a year, company-confirmed in September 2026, with dedicated oncology lines kept separate from the general lines.
-
18.3 M
Oncology liquid vials / yr
-
12 M
Oncology lyophilized vials / yr
-
240 M
Oncology tablets and capsules / yr
-
21.6 M
General liquid vials / yr
-
67.8 M
General lyophilized vials / yr
-
60 M
Propofol vials / yr
-
360 K
Inhaler bottles / yr
By capability
Four ways into the plant
Manufacturing is the base capability everything else builds on; lyophilization is the specialization behind Naprod's oncology injectables; R&D covers formulation and analytical development. Quality & Regulatory governs what the plant is permitted to ship, and where.
-
Manufacturing
The Tarapur, Maharashtra production floor behind the 200+ product catalog across finished dose forms and APIs, run under EU-GMP and WHO-GMP process controls.
-
Lyophilization
Freeze-drying at commercial scale: 12M dedicated oncology vials and 67.8M general vials a year, the capability most closely tied to Naprod’s oncology franchise.
-
Research & Development
Formulation and analytical development behind the catalog and the 24-product official pipeline, feeding future filings across SRA, ROW, and domestic markets.
-
Quality & Regulatory
15+ international accreditations on the register, including EU-GMP, WHO-GMP, ANVISA, INVIMA, EAEU, UAE MOHAP, and NHRA Bahrain.